Document Detail


Feasibility of proliferation studies using the BrdU and MTT assays with a head and neck carcinoma cell line.
MedLine Citation:
PMID:  8336924     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
After the failure of interferon monotherapies for head and neck cancer, an increasing number of combination experiments with chemotherapy and interferons have been carried out to improve the antiproliferative effect. In vitro drug testing requires sensitive assay to detect synergistic effects of tested combinations in order not to get false-negative results. The widely used MTT assay (3,4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide) and the BrdU assay 5-bromo-2-deoxyuridine were compared. It could be shown that the BrdU assay is over 10 times more sensitive and that it reflects the cell proliferation status as shown by flow-cytometric analysis using double staining with BrdU. Labeling with BrdU also allows the estimation of the S phase time. Because of the direct effect of interferons on the cell cycle, the BrdU assay could be appropriate for proliferation studies using interferons.
Authors:
W Bergler; G Petroianu; A Schadel
Related Documents :
991964 - The influence of hyperthyroidism and hypothyroidism on the wound healing of experimenta...
18429114 - Labeling cultured cells with 32p(i) and preparing cell lysates for immunoprecipitation.
17393124 - Superparamagnetic iron oxide labeling of neural stem cells and 4.7t mri tracking in viv...
7137054 - Quantitative autoradiography, electron microscopy, and granulometry of endocrine cells ...
20026904 - Overexpression of angiotensin ii type 2 receptor gene induces cell death in lung adenoc...
6329334 - Development of adenosine responsiveness after isolation of leydig cells.
Publication Detail:
Type:  In Vitro; Journal Article    
Journal Detail:
Title:  ORL; journal for oto-rhino-laryngology and its related specialties     Volume:  55     ISSN:  0301-1569     ISO Abbreviation:  ORL J. Otorhinolaryngol. Relat. Spec.     Publication Date:    1993 Jul-Aug
Date Detail:
Created Date:  1993-08-26     Completed Date:  1993-08-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0334721     Medline TA:  ORL J Otorhinolaryngol Relat Spec     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  230-5     Citation Subset:  IM    
Affiliation:
ENT Department, Klinikum der Stadt Mannheim, University of Heidelberg, FRG.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bromodeoxyuridine
Carcinoma, Squamous Cell / drug therapy
Cell Line
Cisplatin / therapeutic use
Colorimetry
Coloring Agents
Drug Screening Assays, Antitumor*
Feasibility Studies
Head and Neck Neoplasms / pathology*
Humans
Laryngeal Neoplasms / drug therapy
Tetrazolium Salts
Thiazoles
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Coloring Agents; 0/Tetrazolium Salts; 0/Thiazoles; 15663-27-1/Cisplatin; 298-93-1/thiazolyl blue; 59-14-3/Bromodeoxyuridine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  One-year follow-up after tympanostomy tube insertion for recurrent acute otitis media.
Next Document:  Congenital cholesteatoma of the petrous pyramid.